FGF4 promotes resistance to lapatinib in HER2-positive breast cancer cell lines through FGFR1 signalling [136], and FGF5 by inducing FGFR2 activation, which in turns transactivates HER2 and promotes resistance [137]. This evidence concerns the gene FGF4 and breast carcinoma.